Table 5.

Studies of compounds used with some success in both EAE and MS

Compound/class	EAE proof of concept, mechanistic hint, confirmation (references)	MS therapeutic success (references)
Hormones:
• Estriol	(Kim et al., 1999)	(Soldan et al., 2003)
• Testosterone	(Palaszynski et al., 2004)	(Sicotte et al., 2007)
Statins	(Youssef et al., 2002)	(Vollmer et al., 2004)
Quinolones
• Linomide	(Karussis et al., 1993b)	(Comi et al., 2010)
• Laquinimod	(Brunmark et al., 2002)
Tolerizing DNA vaccines	(Waisman et al., 1996; Lobell et al., 1998; Selmaj et al., 2000)	(Bar-Or et al., 2007; Garren et al., 2008)
Antibiotics with immunomodulatory and neuroprotective functions: minocycline	(Brundula et al., 2002; Giuliani et al., 2005a,b)	(Metz et al., 2004; 2009; Zabad et al., 2007; Zhang et al., 2008)
Immunosuppressants
Azathioprine	(Blaszczyk et al., 1978)	Hauser et al., 1983; Hafler et al., 1991; Noseworthy et al., 1993; van de Wyngaert et al., 2001; Hartung et al., 2002; Krapf et al., 2005; Massacesi et al., 2005; Smith et al., 2005; Casetta et al., 2007
Cyclophosphamide	(Mangano et al., 2010)
Mitoxantrone	(Ridge et al., 1985; Lublin et al., 1987)
Haematopoietic stem cell transplantation	(Karussis et al., 1992; Karussis et al., 1993b; Burt et al., 1995; Burt et al., 1998; Karussis et al., 1999; van Bekkum, 2000; Cassiani-Ingoni et al., 2007)	(Muraro et al., 2003; 2005; Burt et al., 2009; Muraro and Uccelli, 2010; Pasquini et al., 2010)
i.v. immunoglobulins	(Achiron et al., 1994; Achiron et al., 2000; Ephrem et al., 2008)	(Achiron et al., 1998; Haas, 2000; Strasser-Fuchs et al., 2000; Katz et al., 2006)